MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

InflaRx NV

Geschlossen

1.02 -7.27

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.99

Max

1.11

Schlüsselkennzahlen

By Trading Economics

Einkommen

12M

-5.1M

Verkäufe

-124K

-423

EPS

-0.08

Gewinnspanne

1,208,456.738

Angestellte

74

EBITDA

12M

-5M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+566.96% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-11M

70M

Vorheriger Eröffnungskurs

8.29

Vorheriger Schlusskurs

1.02

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

InflaRx NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Apr. 2025, 23:55 UTC

Heiße Aktien

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2. Apr. 2025, 22:50 UTC

Wichtige Markttreiber

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2. Apr. 2025, 21:08 UTC

Ergebnisse

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2. Apr. 2025, 21:00 UTC

Ergebnisse

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2. Apr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2. Apr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Apr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2. Apr. 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2. Apr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Apr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2. Apr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Apr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2. Apr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2. Apr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2. Apr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2. Apr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2. Apr. 2025, 22:43 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2. Apr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2. Apr. 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2. Apr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2. Apr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Apr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2. Apr. 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2. Apr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2. Apr. 2025, 20:53 UTC

Ergebnisse

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2. Apr. 2025, 20:52 UTC

Ergebnisse

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer-Vergleich

Kursveränderung

InflaRx NV Prognose

Kursziel

By TipRanks

566.96% Vorteil

12-Monats-Prognose

Durchschnitt 7.67 USD  566.96%

Hoch 10 USD

Tief 5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für InflaRx NV – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.02 / 1.24Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.